NM-32 is under clinical development by Numab Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NM-32’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NM-32 overview
NM32-2668 is under development for the treatment of solid tumor, hematological tumor and mantle cell lymphoma. The drug candidate is a tri-specific antibody which acts by targeting ROR1 antigen, CD3 and human serum albumin (HSA).
Numab Therapeutics overview
Numab Therapeutics (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND021, ND009, ND023, ND026, ND023, ND026, and ND009, ND039, ND040. Its ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease, a chronic inflammation of the digestive tract that includes ulcerative colitis and crohn’s disease. The company’s products are used in the treatment of inflammatory bowel disease, autoimmune disorders and metabolic disorders. It utilizes a proprietary antibody discovery and engineering technology to produce antibody Fv fragments. Numab is headquartered in Wadenswil, Zurich, Switzerland.
For a complete picture of NM-32’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
